Antengene Doses First Patient In Pivotal Phase III ATG-022 Gastric Cancer Trial; Stock Up

Antengene Corporation dosed the first patient in China in the pivotal Phase III CLINCH-3 trial of ATG-022, a CLDN18.2-targeting antibody-drug conjugate. The study advances the commercial-stage biotech's late-stage development program for patients with CLDN18.2-positive disease, although the article excerpt does not provide efficacy, safety, or financial data.